No Data
Wells Fargo Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Maintains Target Price $17
Promising Risk-Reward Scenario for RAPT Therapeutics: A Buy Rating Amid Clinical Uncertainties and Valuation Considerations
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
12 Health Care Stocks Moving In Wednesday's Intraday Session
RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability
Rapt Therapeutics Is Maintained at Neutral by UBS
No Data
No Data